Company: PRME
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050422
Chunk: 31

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 31
---
3TotalCash equivalents:Money market funds$— $178,212 $— $178,212 Corporate debt securities— 3,793 — 3,793 Short-term investment:U.S. Treasury and government securities— 2,998 — 2,998 Related party short-term investment:Beam equity securities4,968 — — 4,968 Total cash equivalents and investments$4,968 $185,003 $— $189,971 The Company classifies its investments as short-term based on each instrument’s underlying contractual maturity date. The fair value of investments classified as Level 2 are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. 

14

Investments in Debt SecuritiesUnrealized gains and losses of investments in debt securities consisted of the following: As of September 30, 2025:(in thousands)Amortized CostUnrealized GainsUnrealized LossesFair ValueShort-term investments in debt securities:U.S. Treasury and government securities$95,744 $38 $(1)$95,781 Corporate debt securities41,253 2 (6)41,249 Total short-term investments in debt securities$136,997 $40 $(7)$137,030 As of December 31, 2024:(in thousands)Amortized CostUnrealized GainsUnrealized LossesFair ValueShort-term investments:U.S. Treasury and government securities$2,997 $1 $— $2,998 Total short-term investments in debt securities$2,997 $1 $— $2,998 The contractual maturities of the Company’s investments in debt securities were as follows:(in thousands)September 30,2025December 31,2024Due within one year$137,030 $2,998 Marketable securities in unrealized loss positions consisted of the following: As of September 30, 2025:(in thousands, except number of securities)Number of SecuritiesFair ValueGross Unrealized LossesInvestments in continuous loss position for less than 12 months:U.S. Treasury and government securities5 $4,489 $(1)Corporate debt securities16 $25,707 $(6)Based on factors such as historical experience, market data, issuer-specific factors, and